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Abstract
Prostate cancer (PCa) is no exception to the multi-step process of metastasis. As PCa progresses,
changes occur within the microenvironments of both the malignant cells and their targeted site of
metastasis, enabling the necessary responses that result in successful translocation. The majority of
patients with progressing prostate cancers develop skeletal metastases. Despite advancing efforts
in early detection and management, there remains no effective, long-term cure for metastatic PCa.
Therefore, the elucidation of the mechanism of PCa metastasis and preferential establishment of
lesions in bone is an intensive area of investigation that promises to generate new targets for
therapeutic intervention. This review will survey what is currently know concerning PCa
interaction with the extracellular matrix (ECM) and the roles of factors within the tumor and ECM
microenvironments that contribute to metastasis. These will be discussed within the context of
changes in expression and functional heterodimerization patterns of integrins, changes in ECM
expression and reorganization by proteases facilitating invasion. In this context we also provide a
brief summary of how growth factors (GFs), cytokines and regulatory signaling pathways favor PCa
metastasis to bone.
Background
Prostate cancer (PCa) is the second most common malig-
nancy in men worldwide [1]. In the United States for 2003
there are expected to be 220,900 new diagnoses and
approximately 28,900 PCa deaths [2]. Notably, it has
been determined that ~90% of patients with advanced
PCa will develop osseous metastases [3,4]. Similar studies
on PCa patients at autopsy have found ≥ 80% of patients
have established macrometastases involving bone, and of
these bone lesions ≥ 90% will have an osteoblastic pheno-
type [5,6]. The characteristics of clinical presentation with
bone involvement include severe pain, pathologic frac-
tures and spinal cord compression [7]. Typically these
patients have a mean survival time of nine months to one
year [8]. Thus, once PCa metastasizes to the bone it is dif-
ficult to eradicate.
Metastasis requires the interaction of malignant cells with
three distinct microenvironments 1) the primary organ, 2)
the circulation, and 3) the target organ where a metastatic
lesion will develop [9-11]. Both soluble and insoluble
stromal elements within these microenvironments are
involved in the metastatic cascade [11]. Successful metas-
tasis requires that several well-documented steps be fol-
lowed. Initially, angiogenesis must be induced to meet the
nutrient needs of the growing cancer cells and facilitate
removal of toxic waste products [12,13]. The metastatic
cells must then degrade or remodel basement membrane,
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detach from the primary tumor mass and intravasate.
Tumor cells must next survive the stress of vascular trans-
portation and evade host defense mechanisms [12].
Attachment to their preferred site of metastasis may be
either targeted, via tissue-specific microvessel cell adhe-
sion molecules (CAMs) [14,15], or more general in nature
simply allowing the tumor cells to reside in the target tis-
sue long enough to respond to transendothelial soluble
factors from the target organ (Sikes, unpublished data)
[11]. Tumor cells then extravasate into the target organ
parenchyma, where they proceed to proliferate in the new,
supportive microenvironment as micrometastases.
Finally, the micrometastases must induce angiogenesis to
support growth of the new lesion [16].
Despite intensive research efforts very little is known
about the specific mechanism(s) that contribute to the
predominant pattern of PCa metastasis and establishment
of bony lesions (Sikes, unpublished data). Various theo-
ries have been proposed, including venous drainage, lym-
phatic spread, and arterial emboli [5]. One of the oldest,
for example, is based on anatomical juxtaposition of the
veins draining into the lower vertebral column and pelvic
girdle from the testes, penis and prostate gland called
Batson's plexus [17,18]. Data indicate that lymphatic
channels are only capable of transporting metastatic cells
to regional nodes, and further dissemination is carried out
through the vascular system [17,18].
Prior to reaching the circulation for transport to and sub-
sequent re-colonization at a metastatic site, PCa cells must
become motile and detach from the primary tumor and
overcome the barrier of the extracellular matrix (ECM).
Cell locomotion is a coordinated balance between adhe-
sion and detachment of cells through CAMs that occurs
simultaneously with tumor cell-induced remodeling of
ECM [19-21]. Tumor cell adhesion may be modulated by
cytokines and growth factors (GFs) that effect CAM
expression and functional organization [22]. To date at
least 50 CAMs have been identified and are divided into
four major families based on protein structure: 1) the Ig
superfamily, 2) the cadherin family, 3) integrins and 4)
selectins [23]. Additionally, upregulation of matrix-met-
allo proteinases (MMPs) and other protease-receptor
pairs, like protease-activated receptor 1 (PAR1), facilitate
invasion through the basement membrane, providing
necessary access to either the lymphatic or vascular circu-
lations [24].
LNCaP and PC-3 (Table 1) models are the two principal
culture-to-animal systems being used to delineate the spe-
cific mechanisms required for bone metastasis, and will
be the focus of experimental data presented in this review,
unless otherwise stated. Particularly, the LNCaP model of
PCa progression [25-27] gives an opportunity to follow
coordinated changes in integrin expression, usage, and
behavior of PCa cells when exposed to different ECM sub-
strata and stromally-derived soluble factors; and is unique
in that all cell lines vary in metastatic potential but share
a common genetic background. Previous phenotypic [27]
and genotypic [28] characterizations of these cell lines
also revealed their remarkable resemblance to the clinical
progression of human prostate cancer. The goals of this
review are to discuss the current data that point to tumor-
and ECM-derived factors as major contributors of PCa
metastasizing to bone, with specific attention to soluble
and insoluble factors, CAMs and proteases that mediate
PCa cell detachment from the primary tumor, migration
and invasion to and through the ECM. At the end of each
section, we will attempt to briefly integrate what the data
demonstrates in light of key paracrine signaling mecha-
nisms in both the tumor and ECM microenvironments,
and explain how we believe these mechanisms may drive
metastatic PCa progression. The various prostate cancer
cell lines discussed in this review are briefly described in
Table 1.
Table 1: Basic Properties of Prostate Cell Lines.
Cell Line Origin Androgen Responsiveness Tumorigenicity
NbE1.4 [151-154] Normal rat ventral prostate Androgen sensitive None
P69 [148,149] Normal Human prostate Androgen independent Very poor
DU-145 [147] Human brain metastasis Androgen independent High
LNCaP [145] Human lymph node metastasis Androgen sensitive Low
C4-2* [113,144] Human castrated mice Androgen refractory High with bone metastases
VCaP [150] Human bone metastasis Androgen sensitive High
PC-3 [146] Human bone metastasis Androgen independent High
*This cell line was derived from the original co-inoculation of LNCaP and bone stromal cells in mice. References for each cell line are as follows: 
LNCaP (Lymph Node Carcinoma of the Prostate), PC-3 (Prostate Cancer-3), DU-145 (Dura-145), and VCaP (Vertebral-Cancer of the Prostate).Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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The extracellular matrix and prostate cancer 
progression
The ECM or basement membrane of most epithelial
sheets is primarily composed of laminin and collagen
type IV (coll IV), as well as other collagen subtypes. In
addition, the ECM also consists of many non-collagenous
molecules such as bone sialoprotein (BSP), osteopontin
(OPN), osteonectin, osteocalcin (OC), fibronectin, vit-
ronectin (VN), and thrombospondin [29]. As PCa
progresses, the expression of many of these components is
up-regulated, down-regulated, or lost all-together. These
differential patterns of expression aid the tumor in ECM
transmigration and ultimately metastasis. For example,
when prostate cells are transformed with the neu onco-
gene, collagen IV is overexpressed in PCa cell lines PC-3
and NbE1.4 [30,31]; while laminin alone is up-regulated
in NbE1.4 [31] and the calcium-independent intercellular
cell adhesion molecule-7 (ICAM-1) is down-regulated in
PC-3 cells [30]. In the LNCaP progression model, BSP
[32,33], OPN [34] and OC [35] are overexpressed in the
more aggressive C4-2 cells. Multiple studies have also
demonstrated changes in expression of ECM molecules in
advanced PCa tumor samples, such as increased expres-
sion of BSP and Cadherin 11 [36,37], or decreased coll VII
expression [38]. Xue et al., found an interesting pattern of
expression in Tenascin-C, a molecule involved in stromal-
epithelial interactions, where low and moderate-grade
tumors showed high levels of the glycoprotein that dimin-
ished in high-grade tumors [39]. In the same study, they
also documented a dramatic loss of laminin expression
indicating a break in the basement membrane adjacent to
the tumor cells. These findings were recently corroborated
by Brar and colleagues [40].
Cadherins and prostate cancer progression
Cadherins include a multigene family of cell surface adhe-
sion glycoproteins, that provide homotypic interactions
between cells and are used to maintain cell:cell associa-
tions or mediate cell migration [41]. Classical cadherins
(E-, N-, and P-cadherin) possess a highly conserved and
characteristic cytoplasmic domain that interacts with their
functional partners, β- or γ- and α-catenin [42]. Loss of
expression of either pair in this functional complex has
been associated with an invasive phenotype due to
reduced cell:cell adhesion [43-45]. E-cadherin is an epi-
thelial-specific, calcium dependent CAM that functions to
maintain epithelial sheet integrity [46]. As carcinomas
become more aggressive with propensity to metastasize,
E-cadherin is often lost [46], making it a good candidate
to be a metastasis suppressor. It may also serve as a useful
prognostic marker for PCa because it is lost with increas-
ing tumor grade and stage [47,48], and down-regulated in
PCa cell lines, PC-3, LNCaP and C4-2 [37,49,50]. The
nature of the down-regulation is by both protein level and
proteolysis resulting in loss of function. Conversely, the
expression of N-cadherin in PC-3 cells [49] and advanced
prostatic carcinomas [37] has been demonstrated to
increase. This would be expected because N-cadherin
expression in highly invasive breast cancers was found to
replace E-cadherin in facilitating cell:cell contacts, and
thought to mediate the interaction between mammary
tumor and stromal cells [51]. It is therefore thought to
contribute to metastasis via mammary stroma migration
[52], and may function similarly in PCa.
In addition to classical cadherins, Bussemakers et al.,
found other cadherins, including -4, -6, and cadherin-11
were also expressed in a number of PCa cell lines such as
PC-3 [37]. In particular, they found an increased expres-
sion of cadherin-11 and one of its splice-variants, previ-
ously associated with dominant-negative regulation of
cell adhesion [53], suggesting it plays a role in PCa pro-
gression [37]. Interestingly, they also showed no detecta-
ble mRNA or protein expression of cadherin-11 in the less
aggressive LNCaP cells.
Role of integrins during progression
The expression of CAMs on cancer cells, as well as on
endothelial cells, is not static, but dynamic and strictly
controlled by mediators such as GFs, cytokines/chemok-
ines, and the composition of the ECM [22,54-58]. Cell
behavior decisions, such as decreasing cell-cell and cell-
substrate attachment, and increasing cell motility are
accompanied by changes in the expression and/or usage
of adhesion receptors,especially those of the integrin fam-
ily [59,60]. Integrins are themselves heterodimeric mole-
cules, consisting of one α and one β subunit, with at least
20 different combinations already described, many of
which differ in their extra- and intracellular binding spe-
cificities [61,62]. Integrin molecular structure, het-
erodimerization, and intra- and extracellular interactions
with cytoplasmic regulatory proteins and ECM ligands
provide tremendous potential for variation among cell
types, well beyond that available through quantitative var-
iation in integrin expression level alone [63].
Since integrins are intimately involved with cell adhesion
and motility, experiments were performed to see if there
were overt changes in the amount of cell surface integrins
expressed in the LNCaP progression model and P69 cell
lines. Compared to the cancer cell lines, P69 has much
higher expression of integrin subunits (Sikes, unpub-
lished data). These data correspond very well with the
strong binding demonstrated in the adhesion assays and
the low metastatic potential of this SV40-immortalized
cell line (Sikes, unpublished data). Essentially, cells that
adhere too well cannot move well. A direct comparison
between the cell lines of the LNCaP lineage revealed very
few changes in the absolute levels of integrin subunit
expression. Only the α2  and  β5  integrins increasedReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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appreciably. While α2β1 was shown to bind laminin (LN)
and collagen [64], our previous work [63] indicates that
this integrin pair is probably not utilized in the LNCaP
progression model to bind LN. Integrin α2β1 also medi-
ates PC-3 cell adhesion to collagen I, which is a major
component of the bone matrix [57]; and was found to
mediate cell adhesion to collagen type II, III and IV as well
[65].
Despite the modest changes in the absolute levels of
integrin subunits, we demonstrated that LNCaP and C4-2
cells have switched the functional pairing of integrin het-
erodimers [63]. As described by Edlund et al., LNCaP uses
primarily α6β4 and not β1 pairs to bind LN, VN and OPN,
while C4-2 uses a combination of α3β1 and αvβ3 integrins
to bind these matrix components [63]. This switch in
integrin heterodimer usage reflects a shift from a junc-
tional integrin expression by LNCaP, α6β4, to a motility
associated pair of integrin heterodimers in C4-2 cells, α3β1
and αvβ3. [63]. Additionally, the α6β1 pair is up regulated
in C4-2 cells and has been associated with both an
increase in metastatic behavior and enhanced cell spread-
ing in many prostate cancer cell lines [31,63]. In tissue, an
increase in α6β1 expression was associated with invasion
of the seminal vesicles by prostate cancer [66]. Cooper et
al., demonstrated that the β1 subunit is involved in PC-3
cell adhesion to fibronectin, a soluble ECM component of
the bone microenvironment [67]. These data would tend
to rule out a direct effect of this integrin in the adhesion
of either LNCaP or C4-2 cells, but does not rule out a role
for this pair in cell motility or invasion, especially consid-
ering that the role of β1 in invasion and motility has been
aptly demonstrated for endometrial cancer [68]. Direct
evidence of this in LNCaP and C4-2 remains to be con-
firmed experimentally.
Refocusing on the LNCaP model, the more metastatic
sublines were distinct in their use of αvβ3 and, when com-
pared with parental cells, showed a shift in α6  het-
erodimerization, a subunit critical not only for interaction
with prostate basal lamina but also for interaction with
the bone matrix [63]. The involvement of the αvβ3 pair is
unusual in epithelial cells since it is usually expressed in
lymphocytes and other migratory cell types [69,70]. It is
clear, however, that C4-2 cells are using αvβ3 integrin het-
erodimers for both adhesion and migration on LN, OPN
and VN, while LNCaP cells do not [63,71,72]. Interest-
ingly, breast and lung cancer cell lines that were derived
from bone marrow aspirates also expressed αvβ3, suggest-
ing that it plays a role in overall metastasis of cancer cells
to bone marrow [70]. PCa cell adhesion to and migration
on components present in the bone matrix are also medi-
ated, in part by αvβ3 [73]. For example, a number of stud-
ies have shown that both breast and PCa cells attach to
bone-specific ECM components following transendothe-
lial migration, including vitronectin and osteopontin
[14,22,29,74,75]. The αvβ3 expressed on PCa cells, is also
a natural receptor for many of the previously mentioned
non-collagenous ECM proteins [22,75-77]; and may give
an indication as to why C4-2 cells, known to spontane-
ously relocate to bone [27], increase their use of this
integrin pair as compared to α6β4. It is also relevant to
note here that compared to a number of other PCa cell
lines, αvβ3 expression was recently determined to be the
greatest in PC-3 cells [11]. Thus, the data suggest that
αVβ3, in part, facilitates PCa metastasis to bone by medi-
ating PCa cell adhesion to and migration on OPN and VN,
two dominant proteins in the bone microenvironment
[59].
The mechanism involved in coordinating the heterodimer
usage between these cell lines has not yet been deter-
mined. Curiously, our FACS analysis of live cells would
indicate that the levels of surface α6 and  β4 have not
changed between LNCaP and C4-2. Even-so, α6β4 use
declined in C4-2 cells, in conjunction with an increased
use of α6β1, αvβ3, and α3β1 [63]. This was reiterated by the
observation that the striking increase in the spreading of
C4-2 cells on LN after treatment with stromal factors
could be completely obliterated by the addition of func-
tion-blocking antibodies against α6 or β1, but not against
α2, α3, β4, or αvβ3 [63]. Since α6β4 heterodimers partici-
pate in both the formation of hemidesmosomesas well as
in the control of cell motility by unique properties of the
β4 integrin [78], it is possible that the β4 subunit or α6β4
heterodimer are actively participating in the motility and
invasive behavior of PCa cells in a manner that is different
from that used by LNCaP cells to attach to a substrate. The
function of the β4 integrin would then be determined in a
context-dependent manner interpreting environmental
cues. In primary prostate carcinomas and established PCa
cell lines (DU-145), the α6 integrin subunit maintains a
persistent expression during PCa progression, and shifts
in β subunit heterodimerization partners were observed
from  α6β4 alone to also include α6β1 pairs [38,79]. In
other tumor cell types, these laminin-binding integrins
(α6β4 and α6β1) have also been linked to acquisition of
invasive behaviors [79,80]. The shift in α6 usage concurs
with previous studies, where α6β1 and  α6β4 were both
found in normal prostate cells, but β4 subunit expression
was lost in carcinomas [38,80,81]. Taken together, these
data indicate that functional changes in surface proteins
that are involved in invasion are likely to occur with or
without major changes in levels of the protein expressed
and that these changes are dependent on the epithelial-
ECM-stromal interactions within the tumor and subse-
quent bone microenvironments (Sikes, unpublished
data).Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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The data also indicate that human prostate cancer has
altered integrin expression when disseminated to the
bone. When cancer tissue was compared to hyperplastic
or benign tissues, the alterations in integrin usage in can-
cer were found in laminin-binding integrin expression in
particular [74,79,82,83]. For example, a number of stud-
ies showed decreases in the expression of the α6β4 integrin
pair [81], β4 expression alone [84] loss of polarity [85]; as
well as decreased α2, α4, and αv expression [86] in more
advanced PCa tissues as compared to non-invasive sam-
ples. Additionally, Murant et al., found an increase in the
β1 subunit as PCa progresses while Zheng et al., docu-
mented once more the trend of increased expression of
the αvβ3 integrin pair in advanced carcinomas [74,87].
Multiple pathways resulting from extracellular and intrac-
ellular signals regulate invasion of a carcinoma cell.
Indeed, cell migration results from the merging of signal-
ing pathways that employ GFs and their receptors, adhe-
sion receptors (integrins) and cytoskeletal elements [88].
In one investigation, Aprikian et al. demonstrated that
αVβ3 was involved in bombesin, a neurotransmitter and a
cancer growth factor, stimulation of PCa cell motility [89].
Neuroendocrine cells in PCa express and secrete bombe-
sin-like peptides, suggesting that these peptides are
involved in PCa progression [89]. Bombesin increased
PC-3 cell invasion through matrigel, but did not alter its
adhesion to ECM proteins including VN [89]. Addition-
ally, bombesin treatment was found to cause β1, β3, and
β5 integrin subunits to coimmunoprecipitate with focal
adhesion kinase (FAK) [89]. Functions of αvβ3in PCa cells
are mediated by FAK, which activates the phosphatidyli-
nositol 3-kinase (PI-3 kinase)/Akt pathway [74,76]. The
PI3K/Akt pathway may also be involved in androgen-
independent growth of PCa [34,90-94]. Once activated by
an upstream kinase such as FAK, this pathway facilitates
cell survival and proliferation by increasing expression of
the cell cycle regulator E2F, which mediates progression
through the cell cycle; as well as prevents the pro-apop-
totic activity of BAD [95,96]. FAK also activates NF-κB,
which is known to regulate the transcription of anti-apop-
totic proteins [96]. PC-3 cells adhered strongly to collagen
type I, a major component of mineralized bone matrix, in
the presence of TGF-β (10 ng/ml), a growth factor found
in high levels in the bone matrix, and this interaction was
mediated by integrins α3β1 and α2β1 [29,57,97,98]. Kiefer
and Farach-Carson [29] demonstrated that PC-3 cell
adhesion to collagen type I stimulated an increase in cyc-
lin D1 expression followed by an increase in cell division.
This implicates the activation of PI3K, map kinase (ERK1/
2) and p70S6 kinase in the collagen-mediated effect on
PC3 cells.
Changes in extracellular matrix proteases
The ECM is a barrier to a progressing cancer cell at both
the primary and metastatic sites. To overcome the ECM
barrier, cancer cells alter their production of specific pro-
teases that degrade components of the ECM. Changes in
several of these proteases have been associated with pros-
tate cancer progression as described below.
Matrix-metalloproteinases (MMP) are a family of zinc-
dependent endopeptidases with broad substrate specifici-
ties for a variety of ECM/BM components, such as colla-
gen types I, II, III and IV, laminin and fibronectin [99]. As
tumor cells grow and divide, they secrete MMPs that break
down the stroma and basement membrane [11]. At the
same time, there is down-regulation of tissue inhibitors of
MMPs (TIMPs) that amplify the process [100]. In fact,
some members of the MMP family of proteases may asso-
ciate with cell membrane receptors able to drive an ori-
ented degradation of ECM and display a disintegrin
region that, by virtue of an RGD motif, play a role in cell-
cell adhesion and cell migration (ADAM proteinases: A
Disintegrin And Metallo proteinase) [101]. Previous stud-
ies have demonstrated the importance of MMPs associ-
ated with tumor and stroma as critical determinants for
ECM deposition, remodeling and the establishment of
PCa metastases in the bone [20,102,103]. Changes in
expression of specific MMPs are reported to be associated
with PCa progression. Lichtinghagen et al., recently dem-
onstrated that MMP-9 protein was significantly higher in
cancerous prostate tissue compared to normal prostate tis-
sue [104]. There was no significant difference in MMP-2
expression between cancerous and normal tissues; how-
ever, there was a significant difference in the ratios of
MMP-2 and MMP-9 to the tissue inhibitor of metallopro-
teinases 1 (TIMP-1), with cancerous tissue having a higher
ratio. Although MMP-2 protein level is not altered during
prostate cancer progression, an earlier study with prostate
cancer cell lines demonstrated that the expression of
membrane-type 1(MT1)-MMP, which activates proMMP-
2 and is expressed on the surface of invasive cells, is up-
regulated in PC-3 and DU-145 cells [105]. Since the main
component of the basement membrane (BM) is collagen
type IV, a substrate for both MMP-2 and MMP-9, it is con-
ceivable that the higher expression of MMP-9 and MT1-
MMP and the higher ratios of MMP-2 and MMP-9 to
TIMP-1 play important roles in the destruction of the BM
necessary for invasion and metastasis.
Neutral endopeptidase (NEP)-24.11 (neprilysin) is
another cell surface metallopeptidase that may be
involved in prostate cancer progression [106]. NEP
degrades a variety of bioactive peptides including
endothelin, which has been implicated in the growth of
hormone refractory prostate cancer. Usmani et al.,
reported that NEP expression was down-regulated inReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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advanced prostate cancer cell lines PC-3 and DU145 com-
pared to LNCaP and normal immortalized prostate epi-
thelial cells [106]. Also, NEP expression was down-
regulated in cells derived from malignant tissues taken
from radical prostatectomies compared to those cells
derived from benign prostatic hyperplasia (BPH). We
speculate that the down-regulation of NEP may contrib-
ute to an increase in bioactive peptides required for pros-
tate cancer growth and metastasis
Cathepsins, a family of cysteine proteases capable of
degrading several ECM components including coll IV,
fibronectin and laminin [107-109]; are up-regulated dur-
ing PCa progression. One study showed that the expres-
sion of Cathepsins (Cath) B and S was higher in prostate
cancer tissue compared to BPH and normal prostate tis-
sues; and, they were frequently co-expressed early in the
development of prostate cancer [110]. Sinha et al.,
reported that CathB activity was elevated in prostate can-
cer tissue samples compared to BPH and normal tissue
samples [111]. This study also showed, by biochemical
and immunogold electron microscopic analysis, the asso-
ciation of CathB with the plasma membrane as well as in
lysosomes [111]. Brubaker et al. recently reported that
CathK was expressed in prostate cancer tissues and not in
normal prostate tissues [112]. The expression was variable
in primary prostate cancer samples and soft-tissue metas-
tases, but was consistently elevated in bone metastases.
Surprisingly, CathK expression in PC-3 cell line, which
was derived from a bone metastasis, was low compared to
DU145 (derived from a brain metastasis) and LNCaP
(derived from a lymph node metastasis). Furthermore,
more advanced sublines, C4 and C4-2, of the LNCaP pro-
gression model, demonstrated decreasing expression of
CathK. Note here, the subline C4-2 has a strong tendency
to metastasize to bone in murine hosts [113]. Together
this information demonstrates that Cathepsins contribute
to prostate cancer metastasis and can be up-regulated by
the bone microenvironment, a preferred site of metastasis.
The activation of protease-activated receptor 1 (PAR1;
thrombin receptor) by thrombin may stimulate prostate
cancer cells to secrete MMPs [11,24]. Chay et al., showed
that PAR1 expression was up-regulated in PCa compared
with normal prostate tissue. This overexpression was very
pronounced in bone-derived PCa cell lines (VCaP and
PC3) compared with soft tissue PCa cell lines (DUCaP,
DU145, and LNCaP), suggesting the PAR1, like CathK, is
up-regulated by stromal factors in the bone marrow
[11,24]. Currently, little is known about the role of PAR1
in prostate cancer progression and studies are underway
to determine the effect of PAR1 stimulation on MMP-9
expression in prostate cancer cells. The exact function of
PAR1 expression and thrombin in PCa metastasis has also
not been delineated; however, these data suggest that
PAR1 enhanced expression on bone-derived PCa cells
may be important in targeting these cells to the bone [11].
The urokinase-like plasminogen activator receptor (u-
PAR) is a membrane-associated serine protease receptor
for urokinase or the urokinase plasminogen activator (u-
PA). U-PAR is a three-domain molecule. Each domain is
numbered 1 to 3 from the amino-terminus to the carboxy-
terminus. Domain 1 is the only domain involved in (pro)-
u-PA binding, domain 3 also participates in providing the
u-PA binding site. The receptor (u-PAR/CD87) focuses the
enzymatic activity of u-PA and allows activation of plas-
minogen (PG) at the cell surface, which in turn, is bound
to the cell membrane by α-enolase receptors [114] or to
other cell surface proteins endowed with C-terminal lysyl
residues, and to plasmin (PL) [101]. PL, a serine protein-
ase, similar to trypsin, acts almost exclusively when asso-
ciated with the plasma membrane, because only in that
location is it resistant to its inhibitor, α 2-antiplasmin
[101]. Plasmin is the main protease involved in (pro)-u-
PA activation, which gives origin to the initiation of the
classical protease cascade (plasmin, interstitial MMPs,
MT1-MMP, Gelatinase A) leading to ECM degradation.
Three extracellular protein ligands involved in ECM deg-
radation and cell adhesion have been identified for u-
PAR, namely u-PA, vitronectin (VN), and kininogen. VN
and the two-chain form of high molecular weight kinino-
gen (HMWK) share overlapping and mutually exclusive
binding sites for u-PAR domains 2 and 3. HMWK-bound
kallikrein (kall) may activate the conversion of u-PAR-
bound (pro)-u-PA to u-PA, thus providing an alternate
pathway to the one triggered by plasmin to (pro)-u-PA
activation. Many indications suggest that the u-PA/u-PAR
system, together with specific inhibitors of plasminogen
activators (PAIs), is an organizer of cell-ECM contacts and
covers the full range of activities required to promote and
disrupt cell attachment sites [115]. PC-3 and C4-2 secrete
more u-PA than LNCaP cells [116,117], which is most
notably involved in the regulation of ECM-laminin degra-
dation, thereby allowing for PC-3 and C4-2 cells to
behave more aggressively. Indeed, in a later study con-
ducted by Festuccia et al., the malignant phenotype of PCa
cells (LNCaP, C4-2, PC-3 and DU-145) was correlated
with both u-PA and u-PAR expression [118]. They found
that differential production of u-PA corresponded with
the ability of the more aggressive lines to bind and activate
plasminogen; thus providing direct support that u-PA
secretion and the levels of u-PA- u-PAR complexes charac-
terize the invasive phenotype of these cells [118]. These
blocking antibody experiments also provided evidence
that this pattern of expression correlates with stage and
grade in prostatic carcinomas, making u-PA or plasmin
candidate target molecules for metastasis-inhibiting
therapeutics.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
Page 7 of 13
(page number not for citation purposes)
Several other molecules interact 'constitutively' with u-
PAR domains 2 and/or 3, thereby functioning as 'corecep-
tors'. These molecules include the α2-macroglobulin
receptor/low density lipoprotein receptor-related protein
(α2MR/LRP), the mannose-6-phosphate receptor
(Man6PR)/ IGFII-receptor, gp130, u-PAR-associated pro-
tein (u-PARAP) and integrins [101]. Integrin family mem-
bers including β1,  β2 and  β3, may interact with u-PAR
domains 2 and 3 as u-PAR co-receptors, which leads to an
enfeeblement of integrin-ECM interactions [119]. If the
cell expresses low or no caveolin, u-PAR-integrin com-
plexes remain loose, floating on unspecialized areas of the
cell membrane, integrin function will be impaired, and
the cell-ECM interaction will rely solely on adhesive inter-
actions mediated by u-PAR-VN [120]. This seems to be the
case for leukocytes and transformed cells, where the
motile properties of the cell must prevail on the cell-ECM
moorings. On the contrary, if the cells express high levels
of caveolin, u-PAR, as with many other GPI-anchored pro-
teins, form clusters on caveolin-rich membrane rafts,
together with the loose integrins. In this case, the complex
"signalosome" of caveolae, rich in kinases of the src fam-
ily, transduce signals leading to integrin overexpression,
which reinforces cell-ECM interactions. This situation has
been recognized in macrophages and metastatic tumor
cells and results in enhanced adhesion and migration on
ECM components [101]. The end result of the involve-
ment of such a large range of signaling molecules is the
activation of several groups of intracellular kinases such as
Src, Src-like protein kinases (Hck and Fgf) and again FAK
with convergence on the extracellular regulated kinase
(ERK)1/2 pathway [121].
Summary and conclusions
The expression of CAMs on tumor cells is not static, but
dynamic, and is regulated strictly by extracellular cues like
soluble GFs, cytokines, and the insoluble proteins com-
posing the ECM [54-58,122,123]. Although a number of
integrin variations during PCa cell progression have been
described [38,74,79-81,124-126], neither modulation of
these variations by external factors nor integrin het-
erodimer usage regulation is well understood [63].
"Inside-out" regulation of integrin heterodimer activity
and subunit partner choices are thought to depend on
unique cytoplasmic regulatory protein repertoires that dif-
fer among host cell types [127-130]. Likewise, "outside-
in" regulation by integrins, in response to extracellular
cues, has revealed shifts in integrin gene expression as well
as changing integrin associations with numerous signal-
ing molecules,including protein tyrosine kinases (FAK
and pp60src), serine kinases (protein kinase C, extracellu-
lar signal-regulated kinase, c-Jun-NH2-terminal kinase,
and integrin-linked kinase), and lipid intermediates (PI3K
and phosphatidylinositol 4,5-kinase) [62,131-133].
Hence, integrin activity within a given cell is tightly coor-
dinated with its cell cycle, gene expression profiles, differ-
entiation, and cell survival [61]. In our studies, few shifts
in integrin expression were found to accompany PCa dis-
ease progression, while integrin heterodimer usage,
changed significantly [63]. Changes in integrin expression
or the functional reassortment of the heterodimers as a
tumor progresses has been studied in both the PC-3 and
LNCaP PCa cell line models but the mechanism has not
been elucidated.
The final component to this story includes the protease-
receptor complexes, which are also molecular organizers
of cell-to-ECM interactions. They coordinate both adhe-
sive and degradative activities necessary to facilitate meta-
static progression [101]. Because traversing the ECM is a
critical step in the invasive process, it is imperative that the
mechanisms driving the conversion of stationary tumor
cells to ones with the capacity to migrate be elucidated.
Various cell-associated serine proteases and their respec-
tive receptors have been shown to up-regulate u-PAR, giv-
ing the u-PA/u-PAR/PAI-1 system prognostic significance
in several tumor types [101], including PCa. As informa-
tion about which u-PAR domains and u-PA sequences
specifically mediate malignant invasion via proteolysis
and adhesion increases, the likelihood of improved
rational drug development to control the factors of the
fibrinolytic system should also increase.
Integrin regulation of prostate epithelial proliferation is
likely to involve interactions between these CAMs and GF
receptors [63]. Such interactions are used by cells to inter-
pret positive and negative GF and cytokine signals from
surrounding stromal cells [134,135], via common signal-
ing cascade components (e.g., small GTPases), also
important for integrin signaling and activation. Preferen-
tial associations between the GF receptors and the chang-
ing integrin heterodimers could have dramatic
consequences on the responses of a cell to environmental
cues [63]. In LNCaP cells, α6β4, is very important for
attachment and would tend to restrict cell migration;
while α6β1 and α3β1, both of which are involved in the
formation of dynamic focal contacts cycled during migra-
tion, are important for cell locomotion [79]. In C4-2 cells,
spreading in response to stromal factors appears to be
mediated through α6β1 which, along with αvβ3 are respon-
sible for migration [63]. Similarly, we found the α6β1 het-
erodimer to be more involved in cell spreading than static
cell attachment in either neu-transformed cells or the
LNCaP progression model [31,63]. The ability of α3β1 to
alter laminin chains and overall basement membrane
architecture [136,137] is particularly suggestive, given that
proteolytic cleavage of laminin can drive cells from static
adhesion to active migration [138,139]. Although β1 was
shown not to be responsible for PC-3 cell invasion, it may
still play a role in C4-2 cell migration/invasion [140].Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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Most notably, the majority of these functions are directed
by α6β4 in LNCaP, suggesting that a functional reassort-
ment of integrins occurs coincident with the acquisition
of additional metastatic traits by C4-2 [140]. Not fre-
quently found in epithelial cells, αvβ3 is common to a
number of bone metastases, including those of prostate
and breast carcinomas [74,126,141]. Two possible conse-
quences of αvβ3  heterodimer usage in the metastatic
LNCaP sublines are (a) preferential relocation to the bone
and (b) increased cell survival/suppressed cell death [63].
Outside of the role of αvβ3 in binding metastatic cells to
the bone matrix, this integrin heterodimer is also a good
candidate regulator of cell survival in the absence of cell
adhesion [63], and thus will remain in the focus of tar-
geted anti-invasive therapies. Although loss of appropri-
ate adhesion is normally a cue for apoptosis, human
breast cancer cells are able to use αvβ3 to inhibit p53 activ-
ity and suppress the bax death pathway [142]. Accord-
ingly, αvβ3 has been shown to regulate cell proliferation in
prostate epithelia [143]. The various patterns of differen-
tial expression of ECM molecules, proteases and integrins
discussed in this review have been summarized in Table 1.
One of the most notable trends in the area of PCa metas-
tasis is the move towards more complicated in vitro and in
vivo systems. This has become necessary since it is now
apparent that studying the individual components,
prostate or bone cells, or other components of their
microenvironments alone, is clearly deficient. These cells
alter their gene expression and migratory behavior in
Table 2: Summary of Molecular Changes Associated with Prostate Cancer Metastasis
Cell line ECM Proteases Integrins
VcaP ↑ PAR [24] ↑αVβ3 [11]
PC-3→PC-3(Neu-T) ↑ CollIV [30] ↑ PAR [24] ↑αVβ3 [11]
PC-3M ↓ ICAM-1 [30] ↑ MT1-MMP [105]
↑ N-Cadherin [49] ↓ NEP [156] ↑α2β1 [97]
↓ E-Cadherin [49] ↑ Cathepsin D [157,158]






LNCaP→C4-2 ↑ OSC [32] ↑ uPA [116] ↑α3β1 (usage) [63]
↑ OPN [27] ↑ PSA [34] ↑α1 (usage) [63]
↑ BSP [32] Cathepsin D (LNCaP) [157,158] ↑αVβ3 (usage) [63]





↑ CollIV [31] ↑α6β1 [31]
Tissues
Benign→Malignant ↑ BSP [160] ↑ Cathepsin BA [110,111] ↑β1 subunit [87]
↑ Cadherin 11 [37] ↑ Cathepsin S [110] ↓α6β4 [81]
↑ N-Cadherin [49] ↑ MMP9 [104] ↑αVβ3
↓ E-Cadherin [87] ↑ Cathepsin K "bone" [112] ↓β4 [84]
↓ Laminin [40] ↑ HK2 [161] ↓β4 (loss polarity) [85]
↑ Tenascin C [39] ↑ MMP2 [162] ↓α2 [86]
↓ Collagen VII [81] ↑ MMP7 [163] ↓α4 [86]
↓ TIMP1 [163] ↓αV [86]
↑ Cathepsin D [164]
↑ MMP26 165
VCaP, PC-3, and DU-145 are advanced prostate cancer cell lines and were compared to the less advanced LNCaP cell line. The information under 
cell lines reflects this comparison. Please note the following: "bone" refers to observations specific for the bone-derived cell lines or malignant tissue 
from the bone, ↑ refers to an increase expression and ↓ refers to a decrease expression, OSC refers to osteocalcin, OPN refers osteopontin, 
superscript A refers to increased activation, MMP is matrix-metalloproteinase and LNCaP→C4-2 refers to LNCaP progression to androgen-
independent C4-2 subline.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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response to co-culture or cross-feeding (personal commu-
nication Dr. Farach-Carson). Furthermore, the only way
to effectively resolve the role of tumor versus ECM factors
in the migration and downstream establishment of boney
metastases will be to examine the behavior of these vari-
ous cells types in structured mutlicellular assays. Candi-
date target proteins can be down regulated using
antibodies, ribozymes or RNAi. Conversely critical pro-
teins can be supplemented to systems of reduced com-
plexity to test for the biological response or re-expressed
in tumor cells to study the effects of their expression. The
individual cells can be followed using fluorescent tags to
visualize cell interactions. Once established, these models
will allow for the functional analysis of ECM proteins,
proteases and integrins involved in the dynamic journey
of PCa cells from their site of origin to their interaction
with factors and cells from the bone milieu that include
ECM, stroma, osteoblasts and osteoclasts, to ultimately
colonize the bone.
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